Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, c… Read more
Market Cap & Net Worth: Duality Biotherapeutics, Inc. (4ZB)
Duality Biotherapeutics, Inc. (F:4ZB) has a market capitalization of $2.91 Billion (€2.83 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #5947 globally and #621 in its home market, demonstrating a -5.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Duality Biotherapeutics, Inc.'s stock price €32.20 by its total outstanding shares 88036264 (88.04 Million).
Duality Biotherapeutics, Inc. Market Cap History: 2026 to 2026
Duality Biotherapeutics, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $2.91 Billion to $2.91 Billion (0.00% CAGR).
Duality Biotherapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Duality Biotherapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4ZB by Market Capitalization
Companies near Duality Biotherapeutics, Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Duality Biotherapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Duality Biotherapeutics, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Duality Biotherapeutics, Inc.'s market cap moved from $2.91 Billion to $ 2.91 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.91 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Duality Biotherapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.91 Billion USD |
| MoneyControl | $2.91 Billion USD |
| MarketWatch | $2.91 Billion USD |
| marketcap.company | $2.91 Billion USD |
| Reuters | $2.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.